Simultaneous predictive value of NT-proBNP and CA-125 in patients newly diagnosed with advanced heart failure: Preliminary results

Archives of Medical Science

Volumn 8, Issue 4, 2012, Pages 637-643

  Folga, Andrzej ^a   Filipiak, Krzysztof J ^a   Mamcarz, Artur ^a   Obrebska Tabaczka, Elzbieta ^b   Opolski, Grzegorz ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b Hospital of Dzialdowo   (Poland)

Author keywords

CA 125; Heart failure; Mortality; NT proBNP; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CA 125 ANTIGEN; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE MARKER; DRUG DOSE TITRATION; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MORTALITY; PATIENT CARE; PRACTICE GUIDELINE; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR; SYMPTOM;

EID: 84866863574     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2012.30287     Document Type: Article

References (17)

1. Mujib M, Desai R, Levitan EB, et al. Prospective population studies of incident heart failure without data on baseline left ventricular ejection fraction. Arch Med Sci 2010; 6: 686-8.
2. Richards M, Troughton RW. NT-proBNP in heart failure: therapy decisions and monitoring. Eur J Heart Fail 2004; 6: 351-4. (Pubitemid 38253056)
3. Masson S, Latini R, Anand IS, et al Val-HeFT Investigators. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem 2006; 52: 1528-38. (Pubitemid 44148316)
4. Perna ER, Macin SM, Cimbaro Canella JP, et al. Importance of early combined N-terminal pro-brain natriuretic peptide and cardiac troponin T measurements for long-term risk stratification of patients with decompensated heart failure. J Heart Lung Transplant 2006; 25: 1230-40. (Pubitemid 44528293)
5. Rienstra M, Van Gelder IC, Van den Berg MP, Boomsma F, Van Veldhuisen DJ. Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-)ANP and (NT-pro)BNP. Europace 2006; 8: 482-7. (Pubitemid 43985484)
6. Waliszek M, Waliszek-Iwanicka A, Grycewicz T, et al. Prognostic value of plasma N-terminal pro-B-type natriuretic peptide concentration in patients with normal and impaired left ventricular systolic function undergoing surgery for abdominal aortic aneurysm. Arch Med Sci 2011; 7: 642-7.
7. Nagele H, Bahlo M, Klapdor R, Schaeperkoetter D, Rodiger W. CA 125 and its relation to cardiac function. Am Heart J 1999; 137: 1044-9. (Pubitemid 30040726)
8. D'Aloia A, Faggiano P, Aurigemma G, et al. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol 2003; 41: 1805-11. (Pubitemid 36584256)
9. Moss EL, Hollingworth J, Reynolds TM. The role of CA125 in clinical practice. J Clin Pathol 2005; 58: 308-12. (Pubitemid 40380329)
10. Miralles C, Orea M, Espana P, et al. Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol 2003; 10: 150-4. (Pubitemid 40485935)
11. Kouris NT, Zacharos ID, Kontogianni DD, et al. The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. Eur J Heart Fail 2005; 7: 199-203. (Pubitemid 40215613)
12. Varol E, Ozaydin M, Dogan A, Kosar F. Tumour marker levels in patients with chronic heart failure. Eur J Heart Fail 2005; 7: 840-3. (Pubitemid 41125903)
13. Turk HM, Pekdemir H, Buyukberber S, et al. Serum CA 125 levels in patients with chronic heart failure and accompanying pleural fluid. Tumour Biol 2003; 24: 172-5. (Pubitemid 37500565)
14. Austin WJ, Bhalla V, Hernandez-Arce I, et al. Correlation and prognostic utility of B-type natriuretic peptide and its amino-terminal fragment in patients with chronic kidney disease. Am J Clin Pathol 2006; 126: 506-12. (Pubitemid 44498499)
15. Bruch C, Reinecke H, Stypmann J, et al. N-terminal pro-brain natriuretic peptide, kidney disease and outcome in patients with chronic heart failure. J Heart Lung Transplant 2006; 25: 1135-41. (Pubitemid 44311523)
16. Racek J, Kralova H, Trefil L, Rajdl D, Eiselt J. Brain natriuretic peptide and N-terminal proBNP in chronic haemodialysis patients. Nephron Clin Pract 2006; 103: c162-72. (Pubitemid 44114504)
17. Faggiano P, D'Aloia A, Bignotti T, Dei Cas L. One biologic marker (carbohydrate antigen-CA 125), two different diseases (ovarian cancer and congestive heart failure): practical implications of monitoring CA 125 serum levels. A case report. Ital Heart J 2003; 4: 497-9.